
GIVE THE PERFECT GIFT
Erin Mills Town Centre Gift Cards are the perfect choice for your gift giving needs.Purchase gift cards at kiosks near the food court or centre court, at Guest Services, or click below to purchase online.PURCHASE HEREHome
Biological Modulation of Solid Tumours by Interferons
Indigo
Loading Inventory...
Biological Modulation of Solid Tumours by Interferons
Current price: $116.09
Original price: $145.12


Biological Modulation of Solid Tumours by Interferons
Current price: $116.09
Original price: $145.12
Loading Inventory...
Size: Kobo eBook
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Indigo
In the 1960s, it was reported that interferons have antitumour activity in different experimental models. Since that time, numerous studies have been performed to elucidate the various mechanisms of action that have been proposed. However, there is much controversy in the literature and promising preclinical findings failed to translate into substantial clinical progress. The present book gives a critical overview of current knowledge of how interferons act in solid tumours. For this purpose, after two chapters of general aspects of interferon action and interaction, selected solid tumours which are commonly considered difficult to treat in advanced stages are discussed with respect to both preclinical data and clinical experience.
In the 1960s, it was reported that interferons have antitumour activity in different experimental models. Since that time, numerous studies have been performed to elucidate the various mechanisms of action that have been proposed. However, there is much controversy in the literature and promising preclinical findings failed to translate into substantial clinical progress. The present book gives a critical overview of current knowledge of how interferons act in solid tumours. For this purpose, after two chapters of general aspects of interferon action and interaction, selected solid tumours which are commonly considered difficult to treat in advanced stages are discussed with respect to both preclinical data and clinical experience.


















